Navigation Links
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a dose-escalating Phase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin (KOS-953) in combination with bortezomib (Velcade(R)), showing a high degree of antitumor activity and tolerability in patients with multiple myeloma who had previously progressed following treatment with multiple conventional therapies. The data were presented on Saturday, June 2, 2007, by Paul Richardson, M.D., Department of Hematology, Dana Farber Cancer Center, Boston, MA, in a poster titled "A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib in Relapsed Refractory Multiple Myeloma" at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Tanespimycin has significant potential as a new treatment for patients with multiple myeloma and is promising in patients with refractory disease whose need for new therapeutic options is especially important," said Dr. Richardson. "The overall profile of tanespimycin in terms of antitumor activity and tolerability, with no additive toxicity to bortezomib, is attractive and we are excited to be moving into later-stage clinical development."

"With the initiation of our TIME clinical program later this year, utilizing our new, superior injectable suspension formulation, tanespimycin will be the first Hsp90 inhibitor to enter registration trials and has the potential to be the first Hsp90 inhibitor to reach the market," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We are highly encouraged by the level of tanespimycin's activity in multiple myeloma and its tolerability and safety profile, and believe that tanespimycin has the potential to represent a breakthrough in the treatment of multiple myeloma. We appreciate th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:9/19/2014)... -- Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia ... an educational program encouraging Hispanics with type 2 diabetes to achieve ... to help reduce the risk of serious health problems. Hispanics in ... risk for developing type 2 diabetes than non-Hispanic white adults, and ...
(Date:9/19/2014)... -- UBM Medica US announces that  OncoTherapy ... oncologists and other clinicians gain a better understanding of ... therapies and immunotherapies, discusses some of the latest news ... Every September, Blood Cancer Awareness Month is ... cancers—helping to increase survival rates and improve the quality ...
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... Calif., Oct. 20 VisionCare Ophthalmic Technologies, Inc., ... individuals with age-related macular degeneration (AMD), today announced ... telescope technology. VisionCare,s investigational telescope implant is the ... approval by the FDA Ophthalmic Devices Advisory Panel ...
... AlphaDetail, an innovator in pharmaceutical marketing research, is pleased ... tracking services: AlphaLink and AlphaMonitor. , AlphaLink helps clients ... with tracking study results. "One of the biggest issues ... data, gathered from a number of different sources," says ...
Cached Medicine Technology:VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 2VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 3AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed 2
(Date:9/19/2014)... U.S. military troops deployed to sunny climates may have ... new study. Many returning troops reported getting ... military personnel developed blisters on their skin or noticed ... their moles since being deployed overseas. All of ... the study authors noted. "The past decade of ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... Ariz. (Sept. 19, 2014) - New research published today ... new Ebola cases could reach 6,800 in West Africa ... measures are not enacted. , Arizona State University ... that the rate of rise in cases significantly increased ... that a mass quarantine was put in place, indicating ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Famous Vancouver ... announced that it has now become a one-stop-solution for ... and businesses in Vancouver. The company has achieved this ... services to its customers. While there are many companies ... to have a single vendor who can offer all ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2
... Vomiting syndrome made him a recluse at times, researcher ... Australian researcher claims he has identified the illness that ... vomiting, headaches and skin problems for most of his ... been suggested for the illness that could be so ...
... gender differences that explain the aging inequity , ... yet another gender inequity: Women develop more and deeper ... do. , The disadvantage had long been suspected, but ... Foad Nahai, a plastic surgeon practicing in Atlanta and ...
... ... of nimotuzumab , ... (PRWEB) December 17, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma ... signing of an agreement under which Therapure Biopharma will provide aseptic fill and finish ...
... 17 Over the last few weeks there has been an ... e cigarette opposition in an attempt to scare the population concerning ... when the evidence clearly shows that the product is indeed a ... opinions from top medial and harm reduction specialist around the world. ...
... , , SAN DIEGO, Dec. 17 CareFusion ... been notified of an unsolicited mini-tender offer by TRC Capital Corporation ... stock, representing approximately 1.8 percent of the shares of common stock ... below the share closing price of CareFusion common stock on Dec. ...
... , , HOUSTON, ... Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin ... for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic ... late-stage development - the rights to which have been ...
Cached Medicine News:Health News:New Theory Emerges on Darwin's Illness 2Health News:Mouth Area Wrinkles More in Women Than Men 2Health News:Mouth Area Wrinkles More in Women Than Men 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 2Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 4Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4
... new AquaGuide Ureteral Access Sheath, you can ... access sheath - plus an entirely new ... sheath is designed with a proprietary dual ... second working channel for a variety of ...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Straight Channel; 33 or 42 cm Working ... Ureteroscopes offer a small distal diameter with ... the ureter for diagnosis and treatment. The ... for large operating instruments, mechanical (Lithoclast) or ...
Semi-Rigid Ureteroscope...
Medicine Products: